If you are interested in interviewing a Sanford-Burnham researcher, please contact Susan Gammon at [email protected].
Highlights of Sanford-Burnham’s data to be presented include:
Oral Presentation
Melanoma• microRNA-211 modulates energy metabolism in human melanoma cells by destabilizing HIF1-alpha and down-regulating PDK4o Ranjan Joseph Perera, Ph.D., presentation # 978, Sunday, April 6, 3:15 p.m.- 5:15p.m., Room 31
Poster Presentations
Brain Cancer• Structural variants shuffle chromatin to activate GFI1 family oncogenes in medulloblastomao Catherine Lee, Ph.D., presentation # LB-203, Tuesday, April 8, 8 a.m.-12 p.m. Hall A-E, Poster Section 40
Breast Cancer• RNF5 mediates ER stress-induced degradation of SLC1A5 in breast cancero Young Joo Jeon, Ph.D., presentation # 2440, Monday, April 7, 1 p.m.-5 p.m. Hall A-E, Poster Section 23• Targeting premalignant lesions for early breast cancer detection and interventiono Aman P. Mann, Ph.D., presentation # 3258, Tuesday, April 8, 8 a.m.-12 p.m. Hall A-E, Poster Section 12
Cancer Metastasis• Membrane pseudokinase PTK7 regulates metastasiso Vladislav Golubkov, Ph.D., presentation # 3009, Tuesday, April 8, 8 a.m.-12 p.m. Hall A-E, Poster Section 3
Drug Delivery Strategies• A tumor-specific tissue-penetrating peptide inhibits metastasiso Kazuki N. Sugahara, Ph.D., presentation # LB-102, Monday, April 7, 8 a.m.-12 p.m. Hall A-E, Poster Section 42• Urokinase plasminogen activator-dependent tumor-penetrating peptideo Tambet Teesalu, Ph.D., presentation # 4504, Tuesday, April 8, 1 p.m.-5 p.m. Hall A-E, Poster Section 29• Targeted therapies and nanoparticle strategies for selective drug deliveryo Hong-Bo Pang, Ph.D., presentation # 5406, Wednesday, April 9, 8 a.m.-12 p.m. Hall A-E, Poster Section 28
Epigenetics• Mycoplasma DNA methyltransferase induces aberrant global hypermethylation and activate cancer-specific genes in human cellso Andrei Chernov, Ph.D., presentation # 2312, Monday, April 7, 1 p.m.-5 p.m. Hall A-E, Poster Section 18
Melanoma• PDK1 in melanoma development and metastasiso Marzia Scortegagna, Ph.D., presentation # 59, Sunday, April 6, 1 p.m.-5 p.m. Hall A-E, Poster Section 3• Tks adaptor proteins and invadopodia formation in the growth and metastasis of melanomao Shinji Iizuka, Ph.D., presentation # 3155, Tuesday, April 8, 8 a.m.-12 p.m. Hall A-E, Poster Section 8• Inhibition of melanoma growth by small molecules that attenuate P13K/PDK1 signaling and promote ATF2 mitochondrial localizationo Giuseppina Claps, M.S., presentation # 4520, Tuesday, April 8, 1 p.m.-5 p.m. Hall A-E, Poster Section 30• Interfering with interferon: An axis of ATF-2mediated chemoresistanceo Eric Lau, Ph.D., presentation # 4901, Tuesday, April 8, 1 p.m.-5 p.m. Hall A-E, Poster Section 9
Prostate Cancer• Small molecule SBI-601 inhibits Siah1/2 ubiquitin ligases, attenuates HIF1-alpha expression and growth of melanoma and prostate cancer cellso Yongmei Feng, Ph.D., presentation # 1795, Monday, April 7, 8 a.m.-12 p.m. Hall A-E, Poster Section 33• The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen-receptor signalingo Ricardo G. Correa, Ph.D., presentation # LB-74, Monday, April 7, 8 a.m.-12 p.m. Hall A-E, Poster Section 41
Join the conversation on Facebook and Twitter using #AACR14.
Sanford-Burnham’s NCI-designated Cancer Research CenterThe Cancer Center is on a mission to discover new revelations about the molecular mechanisms of cancer, with state-of-the-art drug-discovery capabilities, and a team of scientists who are relentless in pursing advances to improve the lives of cancer patients. The Cancer Center is one of seven NCI-designated basic-research cancer centers in the nation, and global leader in turning scientific discoveries into new therapeutic approaches.
About Sanford-Burnham Medical Research InstituteSanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration and stem cells, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center and expertise in drug discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs 1,200 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at sanfordburnham.org.